American Society of Clinical Oncology (ASCO)

The American Society of Clinical Oncology (ASCO) is a professional organization representing physicians of all oncology sub-specialties who care for people with cancer. Founded in 1964 by Fred Ansfield, Harry Bisel, Herman Freckman, Arnoldus Goudsmit, Robert Talley, William Wilson, and Jane C. Wright, it has nearly 45,000 members worldwide.

First-Line Demcizumab/Gemcitabine ± Nab-Paclitaxel in Pancreatic Cancer

ASCO 2016 – GI

Results from a phase 1b study of the anticancer stem-cell agent demcizumab plus gemcitabine with or without nab-paclitaxel in the first-line treatment of patients with pancreatic cancer. Read More ›

BBI608/Gemcitabine/Nab-Paclitaxel in Metastatic Pancreatic Ductal Adenocarcinoma

ASCO 2016 – GI

Results from a phase 1b study of the cancer stem-cell pathway inhibitor BBI608 plus gemcitabine and nab-paclitaxel in treating patients with metastatic pancreatic ductal adenocarcinoma. Read More ›

Tremelimumab plus TACE, RFA, or Cryoablation in Hepatocellular Carcinoma or Biliary Tract Carcinoma

ASCO 2016 – GI

Results of a clinical trial to determine if transcatheter chemoembolization, radiofrequency ablation, and cryoablation can enhance the effect of the CTLA-4 inhibitor tremelimumab in treating patients with hepatocellular carcinoma or biliary tract carcinoma. Read More ›

Molecular Biomarker Stratification of Adjuvant Treatment for Pancreatic Adenocarcinoma

ASCO 2016 – GI

Safety and efficacy results of a phase 2 trial assessing outcomes of patients with resected pancreatic adenocarcinoma treated with gemcitabine plus cisplatin and stratified by tumor excision repair cross-complementing gene-1 (ERCC1). Read More ›

The Cancer Stem-Cell Inhibitor BBI608 plus Paclitaxel in Advanced Pancreatic Cancer

ASCO 2016 – GI

Results of a phase 1b/2 study of the safety and efficacy of the cancer stem-cell inhibitor BBI608 plus paclitaxel in treating patients with advanced pancreatic cancer. Read More ›

Videos

Targeting the VEGF Axis in Advanced NSCLC

ASCO 2016 – Lung Cancer

Benjamin P. Levy, MD, reviews current and emerging roles for agents that target the VEGF axis in advanced non–small-cell lung cancer and expresses his belief that a lot of work needs to be done to define the optimal space for these drugs. Read More ›

Videos

The Future of Immuno-oncology in Advanced Lung Cancer

ASCO 2016 – Lung Cancer

American Society of Clinical Oncology (ASCO)

Page 24 of 33